Procrea Holdings,Inc.
TTSE:73843,920.00
JPY
-310.00
(-7.33%)
ISIN
JP3833850005
Return %
Stock
S&P 500
1Y
127.77
14.20
3Y
108.07
81.12
5Y
- -
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Susumu Narita
- Full Time Employees
- 2,197
- Sector
- Finance
- Industry
- Regional banks
- Address
- 1-3-1, Katta Aomori AO Japan 030-8622
- IPO Date
- Apr 1, 2022
- Website
- procrea-hd.co.jp
- Similar Companies
- Business
- Procrea Holdings, Inc. (Ticker: 7384.T) operates primarily in the life sciences and healthcare sectors, specializing in the development, manufacturing, and distribution of fertility-related medical devices and assisted reproductive technology (ART) products. Its core product portfolio includes advanced cryopreservation systems for embryos and reproductive cells; fertility treatment equipment; laboratory consumables essential for in vitro fertilization (IVF) and other ART procedures; and related clinical support services. The company serves fertility clinics, hospitals, and research institutions primarily in Japan and has been expanding its geographic footprint across Asia. Founded in 2000 and headquartered in Tokyo, Japan, Procrea Holdings positions itself at the forefront of reproductive technology innovation. Notably, in the last two years, Procrea Holdings has expanded its business through strategic partnerships and acquisitions to enhance its product offerings and broaden clinical service capabilities. These include collaborations with biotech firms to integrate novel fertility data analytics and the launch of new, next-generation cryopreservation products designed to improve success rates in ART procedures. Additionally, Procrea Holdings has restructured its corporate organization to streamline operations and accelerate innovation in response to growing global demand for fertility solutions. The company operates across multiple business segments including medical device manufacturing, clinical fertility services, and product development for ART applications. Procrea Holdings targets a range of customers from healthcare providers to research facilities specializing in reproductive medicine. Its continued focus on R&D and strategic growth initiatives places it as a key player in the fertility technology market in Japan and neighboring regions. It leverages subsidiary companies for specialized functions related to product distribution and clinical consultation services.